دورية أكاديمية
Retrait du rofecoxib (Vioxx): a propos de la securite cardiovasculaire des anti-inflammatoires non steroidiens cox-2 selectifs. ; Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?
| العنوان: | Retrait du rofecoxib (Vioxx): a propos de la securite cardiovasculaire des anti-inflammatoires non steroidiens cox-2 selectifs. ; Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs? |
|---|---|
| المؤلفون: | Scheen, André |
| المصدر: | Revue Médicale de Liège, 59 (10), 565-9 (2004) |
| بيانات النشر: | Université de Liège. Revue Médicale de Liège |
| سنة النشر: | 2004 |
| المجموعة: | University of Liège: ORBi (Open Repository and Bibliography) |
| مصطلحات موضوعية: | Cardiovascular Diseases/chemically induced, Clinical Trials as Topic, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Cyclooxygenase Inhibitors/administration & dosage/adverse effects, Humans, Isoenzymes/antagonists & inhibitors, Lactones/administration & dosage/adverse effects, Membrane Proteins, Product Surveillance, Postmarketing, Prostaglandin-Endoperoxide Synthases, Sulfones/administration & dosage/adverse effects, Human health sciences, Pharmacy, pharmacology & toxicology, Sciences de la santé humaine, Pharmacie, pharmacologie & toxicologie |
| الوصف: | peer reviewed ; Rofecoxib (Vioxx), the first COX-2 selective non-steroidal anti-inflammatory drug (NSAID), was recently withdrawn by Merck Sharp & Dohme. Indeed, both observational studies and randomised clinical trials showed that rofecoxib is associated with a significantly increased risk of acute myocardial infarction in patients receiving either high daily dosage (>25 mg/day) or for a long period of time (> 18 months). The precise mechanism responsible for this phenomenon still remains unknown. Currently available data suggest that this adverse effect is not observed with other COX-2 NSAIDs, especially celecoxib for which the information is most abundant. Nevertheless, caution is required because of lack of prospective long-term data, and strict respect of indications and modalities of clinical use of COX-2 NSAIDs is mandatory. Finally, in patients with high cardiovascular risk who should receive a COX-2 selective NSAID, the association with a low dose of acetylsalicylic acid is recommended in order to benefit of a protective antiplatelet effect. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | French |
| تدمد: | 0370-629X 2566-1566 |
| العلاقة: | http://www.rmlg.ulg.ac.beTest; urn:issn:0370-629X; urn:issn:2566-1566; https://orbi.uliege.be/handle/2268/10255Test; info:hdl:2268/10255; https://orbi.uliege.be/bitstream/2268/10255/1/200410_06.pdfTest; scopus-id:2-s2.0-9644289351; info:pmid:15623076 |
| الإتاحة: | https://orbi.uliege.be/handle/2268/10255Test https://orbi.uliege.be/bitstream/2268/10255/1/200410_06.pdfTest |
| حقوق: | open access ; http://purl.org/coar/access_right/c_abf2Test ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.BBA772E2 |
| قاعدة البيانات: | BASE |
| تدمد: | 0370629X 25661566 |
|---|